Navigation Links
Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders
Date:11/7/2008

KANSAS CITY, Mo., Nov. 7 /PRNewswire/ -- In refusing to a request for a special shareholders meeting to consider the removal and replacement of its current directors, management of Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts ("ADRs) are traded on NASDAQ, has apparently decided that the preservation of their jobs and positions in the company outweigh the right of shareholders to meet for the purpose of considering their job performance.

On October 16, 2008, a group of Trinity Biotech ADR holders sent a request to Trinity Biotech calling for the convening of a special meeting of Trinity Biotech shareholders to consider the removal of the current Trinity Biotech directors and their replacement by a slate nominated by the ADR holders who requested the meeting. Thomas Reidy, a member of the group, announced today that company management had advised him by letter dated November 5, 2008 that they would not call the special meeting as requested.

In their refusal letter, the Trinity Biotech directors stated that their denial was based on a determination that the ADR holders, as contrasted with the ordinary shares they represent, do not have the authority under Irish law to call the meeting.

Commenting on Trinity Biotech's refusal to call the special meeting, Mr. Reidy stated that he was "disappointed but certainly not surprised" by the position taken by current management. Mr. Reidy pointed out that the group's original letter requesting the special meeting contains a demand that the Trinity Biotech directors take alternative steps to effectuate the special meeting if management is of the opinion that the requesting ADR holders did not have the authority under Irish law to convene the meeting. Management's refusal letter was silent regarding these alternative steps.

Mr. Reidy stated, "Management's refusal to honor our request or to take the alternative steps proposed to bring our proposal before the company's shareholders can only be viewed as a further step by management to remain entrenched in their positions and beyond any accountability to the owners of the company."

Mr. Reidy continued, "Trinity Biotech management has benefited by accessing American and European equity capital markets through the sale of ADRs. As a result over 90% of the company's ownership is evidenced by ADRs. Management has welcomed our investment but now chooses to disenfranchise us when their performance is called into question and their jobs are on the line. Apparently, management has concluded that their past performance is such that they would be unable to convince a majority of shareholders to vote for their retention."

Mr. Reidy went on to say, "This latest decision only further demonstrates that this board has lost touch with its fiduciary responsibilities. As we have said in the past, this board needs to be removed and replaced by directors who are committed to acting in the best interest of the company and its owners."

Mr. Reidy stated that he would continue in his efforts to bring about the special shareholder meeting. Such efforts might include converting ADRs into the ordinary shares they represent. Mr. Reidy anticipated that other ADR holders would join him in these efforts.

Safe Harbor Statement

Statements in this release that are not historical are forward-looking statements, including statements regarding Mr. Reidy's beliefs, expectations, hopes or intentions regarding the future. It is important to note that actual outcomes and results could differ materially from forward-looking statements. Mr. Reidy assumes no obligation to update any forward-looking statement.

Contact: Thomas J. Reidy, 816-260-8476


'/>"/>
SOURCE Thomas J. Reidy
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
2. Trinity Biotech plc to Announce Third Quarter 2008 Financial Results on October 31, 2008
3. Trinity Biotech plc to Announce Second Quarter 2008 Financial Results on July 22, 2008
4. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
5. InterMune to Present at Deutsche Bank Biotech Boston Confab
6. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
7. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
9. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
10. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
11. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics (OTCQB: ... personalized immune therapies for solid tumor cancers, today ... million financing it announced last Friday, March 17, ... several institutional investors securities totaling 28,843,692 shares, comprised ... and 10,000,000 shares of Class C Warrants pre-funded ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... New Orleans, La. (PRWEB) , ... March 23, ... ... of real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” ... for APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):